A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: ##STR00001## wherein n=1-4; X is C or N; R.sup.1--R.sup.6 can be the same or different and are independently selected from the group consisting of H, C.sub.1-6 alkyl, OCH.sub.3, OH, F, Cl, Br, CH.sub.2OH, CH.sub.2N(R.sup.7).sub.2, C(O)R.sup.8, CH.sub.2CN, CF.sub.3; wherein R.sup.7 is H or C.sub.1-6 alkyl; and R.sup.8 is C.sub.1-6 alkyl or aryl. The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.